Why the study?
Despite the updated 2022 ESC guidelines defining the diagnosis and management of LQTS, uncertainties remain regarding its treatment.
Answers are grounded in this paper and cite their sources.
This commentary provides insights into the 2022 ESC guidelines for Long QT syndrome, focusing on the clinical applications of drug therapies for its various subtypes.
Long QT syndrome (LQTS) is an uncommon disorder that is characterized by QT prolongation and torsade de pointes leading to sudden cardiac death. It is mainly triggered by adrenergic activation. Since LQTS is rare, it is often underdiagnosed. The updated 2022 European Society of Cardiology (ESC) guidelines aim to define the diagnosis of LQTS and spread its management. However, some unknowns and uncertainties still exist regarding the treatment of LQTS. This commentary is geared to the expansion of clinical applications of drug therapies for different subtypes of LQTS based on the 2022 ESC guidelines.
No takes yet. Share an insight, caveat, or question.
Wang et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: